Path is an international nonprofit organization headquartered in Seattle that invents and advances vaccines, therapeutics, diagnostics, medical devices, and health-system innovations aimed at solving pressing public-health challenges in low-income regions, primarily across Africa and Asia. Its portfolio spans research, development, and deployment of solutions targeting diseases such as intestinal worms, malaria, and other neglected tropical illnesses. The organization collaborates closely with governments, academic institutions, and commercial partners to take scientific discoveries from laboratory to large-scale implementation. A current strategic priority is securing U.S. Food and Drug Administration approval for tribendimidine (TrBD) to treat hookworm infections, the first step toward mass deworming campaigns via the Tribendimidine Consortium it leads. Partners in this consortium include the Chinese CDC’s National Institute of Parasitic Diseases, manufacturer Shandong Xinhua Pharmaceutical Company, and the Swiss Tropical and Public Health Institute. Path plans to channel its newly raised capital into accelerating this work on soil-transmitted helminth infections. No revenue or user metrics were disclosed in the article, reflecting the nonprofit nature of the organization.

Total raised

$25M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2017